title: Effects of dialysis on the pharmacokinetics of salazosulfapyridine.
abstract: There was no standard or report for the treatment of rheumatoid arthritis (RA) patients on hemodialysis with Salazosulfapyridine (SASP). We examined the pharmacokinetics of SASP and its metabolites in RA patient on hemodialysis. Hemodialysis was started 2 h after administration of SASP at a dose of 250 or 500 mg. Blood samples were took 8 times during the observation period. The concentration of SASP and its metabolites (SP, Ac-SP) in blood sample were measured. There was no difference for the concentration of SASP before and after hemodialysis. Results showed SASP was nondialyzable, but SP and AC-SP were dialyzable. At a dose of 500 mg, AUC0-∞ of SASP and SP were higher than healthy volunteer. Therapy with SASP for hemodialysis RA should be started at a lower dose for adverse event risk.
authors.affiliation: Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan. inami@juntendo.ac.jp
authors.forename: Yuko
authors.initials: Y
authors.lastname: Inami
authors.forename: Ken
authors.initials: K
authors.lastname: Yamaji
authors.forename: Michiko
authors.initials: M
authors.lastname: Sato
authors.forename: Tomohito
authors.initials: T
authors.lastname: Gohda
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Io
authors.forename: Masuyuki
authors.initials: M
authors.lastname: Nawata
authors.forename: Chieko
authors.initials: C
authors.lastname: Hamada
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Takasaki
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Tomino
mesh_terms: D018501:Antirheumatic Agents / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008875:Middle Aged; D006435:Renal Dialysis; D013427:Sulfapyridine / Q000097:blood; D012460:Sulfasalazine / Q000493:pharmacokinetics*
chemical_list: D018501:Antirheumatic Agents; D012460:Sulfasalazine; D013427:Sulfapyridine
references.citation: Ryumachi. 2003 Jun;43(3):569-76
references.pmid: 12910967
references.citation: Br Med J (Clin Res Ed). 1983 Oct 15;287(6399):1102-4
references.pmid: 6138117
references.citation: J Rheumatol. 2002 Dec;29(12):2492-9
references.pmid: 12465141
references.citation: Drugs. 2005;65(13):1825-49
references.pmid: 16114981
references.citation: Arthritis Rheum. 2008 Jun 15;59(6):762-84
references.pmid: 18512708
references.citation: Ryumachi. 1991 Jun;31(3):327-45
references.pmid: 1683015